Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia - Test2 - elhamkhani - TriplyDB

Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia

Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia

http://www.wikidata.org/entity/Q28236628

about

The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer Regulation of TGF-β signal transduction by mono- and deubiquitylation of Smads Myeloid malignancies: mutations, models and management Tif1γ regulates the TGF-β1 receptor and promotes physiological aging of hematopoietic stem cells Lentivirus-mediated RNA interference of tripartite motif 68 inhibits the proliferation of colorectal cancer cell lines SW1116 and HCT116 in vitro Dynamic regulation of Tgf-B signaling by Tif1γ: a computational approach.The E3 ubiquitin ligase tripartite motif 33 is essential for cytosolic RNA-induced NLRP3 inflammasome activation.Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle.Tumour suppressor TRIM33 targets nuclear β-catenin degradation TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia Autoantibodies to transcription intermediary factor TIF1β associated with dermatomyositis.TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome TiF1-gamma plays an essential role in murine hematopoiesis and regulates transcriptional elongation of erythroid genes Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein.Macrophage production and activation are dependent on TRIM33.Common pathways of autoimmune inflammatory myopathies and genetic neuromuscular disorders.Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.An evolutionary perspective on chronic myelomonocytic leukemia.Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.Turning the tide in myelodysplastic/myeloproliferative neoplasms.TRIM33 is essential for osteoblast proliferation and differentiation via BMP pathway.Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer.Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.Adenovirus E4orf3 targets transcriptional intermediary factor 1γ for proteasome-dependent degradation during infection.Trim33 is essential for macrophage and neutrophil mobilization to developmental or inflammatory cues.The TIF1α-related TRIM cofactors couple chromatin modifications to transcriptional regulation, signaling and tumor suppression.Hematology Testing in Mice.Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer.TRIM proteins in blood cancers.Anti-transcription intermediary factor 1γ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer.[TIF1γ: a tumor suppressor gene in chronic myelomonocytic leukemia].The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.Ubiquitination and deubiquitination emerge as players in idiopathic pulmonary fibrosis pathogenesis and treatment.

P2860

Q21128760-4F97B581-5407-4359-A778-FB29369638B5 Q26827667-4D5D8152-FDBF-4CED-91CA-516E0A124450 Q27000577-DC347DB1-22EB-4B28-A4B6-B80E867FD02D Q28243485-F47C423F-87E3-4299-B256-6414403C23FC Q33598835-6F08EA05-2AD6-4DEE-90F0-E424D65C6E67 Q34213815-C34E70DD-AE97-4866-8015-045922BC2A55 Q34218656-2E8741AF-81AE-497F-83AD-AB06DF6A7CE6 Q34791339-BEC63BD4-2218-44D5-9939-DDBAA74A84E5 Q35043217-7F0AF337-29E7-418B-8D88-6E297DD0F329 Q35651935-0873F50B-6E03-4608-9F9F-F118132FD795 Q35836896-43E79C56-37D7-405A-A5A9-621B4A97276D Q36245820-499E3730-434E-4826-969A-1598C66B16BC Q36414270-263A7A07-E571-40F1-9EFC-A29D725E6972 Q36520899-F2B0C11D-6648-4A37-A7BC-D12E9E9EC42C Q36627526-8DD23AB6-D918-467B-AAF8-612EA1C9B9D6 Q36876853-58973716-7091-4931-9A36-C8B2D817E103 Q36936451-41E152D2-A80F-4F25-9E68-D25A7D1344A7 Q37161750-5ED4A029-4C0C-4261-80B5-7E5EC0594B50 Q37289213-10B92206-984E-4E3F-BF27-3B64046E9861 Q37706314-B953594E-7F26-43D9-8AE8-632836FA6295 Q37956169-3C041416-F726-4AB2-AE24-CF7F60EBDC46 Q37993420-26A75BCF-6C0F-4D33-AB9A-B923C62D0AF6 Q38096235-9A1F32E3-C2FE-44AE-8480-C2304F33EE7D Q38241774-A56FBEB7-8D15-4820-9931-1DEDB72E92BD Q38596370-839E4AFC-23C8-4CCD-A276-533CEB2CF97E Q38712988-177CF1BE-1A99-404A-B29E-8124D51D20D1 Q38722523-62FFDB3A-E7AD-484E-BCEC-BF7FF0FA3FD7 Q38876622-6E54615C-3521-465E-8976-8C2090819AF2 Q38982192-4F8B6A79-4127-47E9-BB78-234664D0377E Q39421013-84C26621-2F5B-4637-AF5F-138258BFBC2A Q40127502-336C9748-2F06-4937-BE43-64ACEE46DDC6 Q40645850-6657CB1E-59DF-47F8-BBAD-8101DC7F7FEB Q40841674-C6EF07A1-9107-4E9C-B359-319A0EE1A1F5 Q41485219-9860A631-56E0-4F81-9D5A-90AD0C80B5D6 Q47433060-C44A4BA2-E4B7-4531-AA6F-C953CF493143 Q48227990-B2056CDF-9E07-4422-83A8-C2A0061C72FA Q53282390-D8F1FA91-ECAE-4BE4-BD5A-1761980D3A88 Q53347165-EA926C46-DA15-4BE2-9563-5FABA4A6652B Q53830978-A622C2F0-919C-43E8-89F8-1EF00E8CD8C1 Q55371625-F34B97D4-DBFC-4A0B-BC07-0E6B8091CC40

P2860

Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia

http://www.wikidata.org/entity/Q28236628

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@ast

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@en

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@nl

type

label

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@ast

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@en

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@nl

prefLabel

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@ast

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@en

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@nl

P1433

Q28236628-2187F957-EAA2-47AF-B39D-8F525D205318

P1476

Q28236628-635DE19F-1894-405D-80F9-FDB13B121DB1

P2093

Q28236628-06F735EB-AFB8-4AF9-9192-FE0404F8977F

Q28236628-0EF1421B-D524-4E49-B6DF-30D1178208B3

Q28236628-23AECB44-1633-4A53-96EF-66073C1FE8F8

Q28236628-4266B28A-BF37-434B-9274-CD16459FCB18

Q28236628-4AEF0325-688F-493B-A39E-3650B6627A8F

Q28236628-4E814D5A-1E11-4FC8-90F3-C8BB0E55D9A6

Q28236628-6598FCF7-9C42-460B-8034-A9F2CC5E355D

Q28236628-73690928-E602-49B4-B12F-FBFA504CE3D4

Q28236628-78F412D8-FE24-4070-A5A1-85A86CCD69F6

Q28236628-894F3BF1-B5CC-4F28-8550-2AA7DC43B2EC

P2860

Q28236628-051E11FA-E6CD-41E5-981D-5EF003DB2EAD

Q28236628-0D033A3D-E31D-42EF-9A0C-172E784DDA9E

Q28236628-19ABA903-FF0B-44AF-B153-1070F210672A

Q28236628-1A2FFE65-03AF-40EE-931C-21FC401827F8

Q28236628-1AB3771B-A15E-4F8F-AE7C-015A0786A1F6

Q28236628-1E91D06D-90A1-4FC9-B02C-94D95757DD3A

Q28236628-1EDF0043-6CB6-4130-8D1E-04A7F407C86E

Q28236628-21097251-9373-4B36-8B62-3BD42F701A21

Q28236628-22ECB0D2-1064-4577-B6F4-08867553C537

Q28236628-2568A12C-E88E-4AF9-ADB6-EE04A3C65B09

P304

Q28236628-A0B24B82-2AD5-429F-8706-3F267561F628

P31

Q28236628-F41EAF4F-95F4-4D22-9C38-9F6947101FA3

P356

Q28236628-5DCC600B-67E4-4D90-9466-856C838FB507

P407

Q28236628-A92626CA-EB10-4607-9B2C-8F735ECE5C16

P433

Q28236628-B3707854-70B5-42F8-AA23-44ABD1A830E0

P478

Q28236628-5308E5E9-8EF5-49CF-BAC7-FA24976C020A

P50

Q28236628-60ACB8FE-9852-4881-BA23-3729EAAFFB49

Q28236628-640EF908-02AC-41FC-88F6-3AA74B28AF02

P577

Q28236628-C2CDF6D7-994E-44E5-B9F9-D3DA368B20D4

P5875

Q28236628-B5EE05AF-712F-482D-BF87-F84A851E24A1

P698

Q28236628-BEB8FC9C-432F-446D-801E-14556BEE7038

P921

Q28236628-BD3D3780-EEF5-47D7-8092-FCF01672863B

P932

Q28236628-F7381297-EEF8-4D0B-B037-A6D43C92A9E9

P356

P1433

Journal of Clinical Investigation

P1476

Transcription intermediary fac ...... hronic myelomonocytic leukemia

@en

P2093

Amandine Bataille

http://www.w3.org/2001/XMLSchema#string

Anne Largeot

http://www.w3.org/2001/XMLSchema#string

Arlette Hammann

http://www.w3.org/2001/XMLSchema#string

Brice Lagrange

http://www.w3.org/2001/XMLSchema#string

Jean-Noël Bastie

http://www.w3.org/2001/XMLSchema#string

Jérôme Paggetti

http://www.w3.org/2001/XMLSchema#string

Kai-Ping Yan

http://www.w3.org/2001/XMLSchema#string

Laurent Delva

http://www.w3.org/2001/XMLSchema#string

Laurent Martin

http://www.w3.org/2001/XMLSchema#string

Nathalie Droin

http://www.w3.org/2001/XMLSchema#string

P2860

TIF1gamma, a novel member of the transcriptional intermediary factor 1 family

A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins

A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination

Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1

KAP-1, a novel corepressor for the highly conserved KRAB repression domain

Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells

TIF1gamma controls erythroid cell fate by regulating transcription elongation

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

P304

2361-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI45213

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51093107

http://www.w3.org/2001/XMLSchema#string

P698

21537084

http://www.w3.org/2001/XMLSchema#string

P921

P932

3104753

http://www.w3.org/2001/XMLSchema#string